Пачуашвили Н. В., Тертычный А. С., Демура Т. А., Порубаева Э. Э., Урусова Л. С.
DOI: https://doi.org/10.17650/2618-7019-2024-7-1-19-30
PDF: https://journal.oncopathology.ru/article/op_2024_1-19-30.pdf
Цель обзора – описание эпидемиологических, клинических, патологических характеристик и прогноза адренокор‑ тикального рака (АКР) с фокусом на последних опубликованных данных, касающихся иммунного микроокружения опухоли. Адренокортикальный рак – это редкая злокачественная эндокринная опухоль коры надпочечника с частотой встречаемости 0,7–2,0 случая на 1 млн населения в год. Из-за трудностей диагностики часто АКР обнаруживается уже на стадии метастазирования, что ограничивает возможности хирургического вмешательства, и сопровождается неблагоприятным прогнозом. Состав микроокружения опухоли имеет решающее значение для разработки стратегии иммунотерапевтического лечения рака. Одним из компонентов микроокружения опухоли являются иммунные клетки, наличие которых нередко ассоциируется с лучшим прогнозом для пациентов. Различные субпопуляции иммуноцитов могут оказывать разнонаправленное действие на опухолевый рост: они могут как стимулировать, так и подавлять прогрессию опухолей в зависимости от спектра вырабатываемых ими цитокинов. Заключение. Применение single-cell анализа для оценки иммунного микроокружения открывает новые перспек‑ тивы для понимания механизмов развития и прогрессирования заболеваний, а также для разработки более эффек‑ тивных иммунотерапевтических стратегий.
Н.В. Пачуашвили1, 2, А.С. Тертычный2, Т.А. Демура2, Э.Э. Порубаева1, Л.С. Урусова1
1 ГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России; Россия, 117292 Москва, ул. Дмитрия Ульянова, 11;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России; Россия, 119048 Москва, ул. Трубецкая, 8, стр. 2
1. Zhang A., Miao K., Sun H. et al. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci 2022;18:3019–33. DOI: 10.7150/ijbs.72534
2. de Visser K.E., Joyce J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 2023;41:374–403. DOI: 10.1016/j.ccell.2023.02.016
3. Dasiewicz P., Moszczyńska E., Perek D. et al. Adrenocortical carcinoma – 12-year observation period in a single centre. Case report with literature review. Pediatr Endocrinol Diabetes Metab 2023;29:202–8. DOI: 10.5114/pedm.2023.132131
4. Gagnon N., Boily P., Alguire C. et al. Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant. Endocrine 2020;68:203–9. DOI: 10.1007/s12020-020-02209-4
5. Habra M.A., Sukkari M.A., Hasan A. et al. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer 2020;146:1836–40. DOI: 10.1002/ijc.32534
6. Cheng Y., Kou W., Zhu D. et al. Future directions in diagnosis, prognosis and disease monitoring of adrenocortical carcinoma: novel non-invasive biomarkers. Front Endocrinol (Lausanne) 2022;12:811293. DOI: 10.3389/fendo.2021.811293
7. Else T., Kim A.C., Sabolch A. et al. Adrenocortical carcinoma. Endocr Rev 2014;35:282–326. DOI: 10.1210/er.2013-1029
8. Jasim S., Habra M.A. Management of Adrenocortical Carcinoma. Curr Oncol Rep 2019;21(3):20. DOI: 10.1007/s11912-019-0773-7
9. Kostiainen I., Hakaste L., Kejo P. et al. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. Endocrine 2019;65:166–74. DOI: 10.1007/s12020-019-01918-9
10. Iñiguez-Ariza N.M., Kohlenberg J.D., Delivanis D.A. et al. Clinical, biochemical, and radiological characteristics of a single center retrospective cohort of 705 large adrenal tumors. Mayo Clin Proceedings Innov Qual Outcomes 2018;2:30–9. DOI: 10.1016/j.mayocpiqo.2017.11.002
11. Pearlstein S.S., Conroy P.C., Menut K.C. et al. Evaluation of necrosis as a diagnostic and prognostic indicator in adrenocortical carcinoma. JAMA Surg 2021;156:1173–4. DOI: 10.1001/jamasurg.2021.3646
12. Selivanova L.S., Roslyakova A.A., Kovalenko Y.A. et al. Current criteria for the diagnosis of adrenocortical carcinoma. Arkh Patol 2019;81:66–73. DOI: 10.17116/patol20198103166
13. Nosé V., Gill A., Teijeiro J.M.C. et al. Overview of the 2022 WHO classification of familial endocrine tumor syndromes. Endocr Pathol 2022;33:197–227. DOI: 10.1007/s12022-022-09705-5
14. Kanjilal B., Ghosh M., Mitra A. et al. Cytological diagnosis of adrenocortical carcinoma: A report of 2 cases in children. Diagn Cytopathol 2018;46:1064–7. DOI: 10.1002/dc.24056
15. Tkachuk A.V., Tertychnyi A.S., Beltsevich D.G. et al. Adrenocortical cancer: Morphological variants, immunohistochemical characteristics. Arkh Patol 2021;83:10–8. DOI: 10.17116/patol20218302110
16. Mills J.K., Khalil M., Pasieka J. et al. Oncocytic subtypes of adrenal cortical carcinoma: Aggressive in appearance yet more indolent in behavior? Surgery 2019;166:524–33. DOI: 10.1016/j.surg.2019.05.049
17. Mete O., Erickson L.A., Juhlin C.C. et al. Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr Pathol 2022;33:155–96. DOI: 10.1007/s12022-022-09710-8
18. Weiss L.M., Medeiros L.J., Vickery A.L.J. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202–6. DOI: 10.1097/00000478-198903000-00004
19. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163–9. DOI: 10.1097/00000478-198403000-00001
20. Bisceglia M., Ludovico O., Di Mattia A. et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 2004;12:231–43. DOI: 10.1177/106689690401200304
21. Urusova L., Porubayeva E., Pachuashvili N. et al. The new histological system for the diagnosis of adrenocortical cancer. Front Endocrinol 2023;14:1218686. DOI: 10.3389/fendo.2023.1218686
22. Ettaieb M.H.T., van Kuijk S.M.J., de Wit-Pastoors A. et al. Development and internal validation of a multivariable prediction model for adrenocortical-carcinoma-specific mortality. Cancers (Basel) 2020;12(9):2720. DOI: 10.3390/cancers12092720
23. Lim J.S., Lee S-E., Kim J.H. et al. Characteristics of adrenocortical carcinoma in South Korea: a registry-based nationwide survey. Endocr Connect 2020;9:519–29. DOI: 10.1530/EC-20-0196
24. Kong J., Zheng J., Cai J. et al. A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study. Cancer Commun (Lond) 2019;39(1):80. DOI: 10.1186/s40880-019-0426-0
25. Duregon E., Molinaro L., Volante M. et al. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol 2014;27:1246–54. DOI: 10.1038/modpathol.2013.230
26. Fassnacht M., Johanssen S., Quinkler M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009;115:243–50. DOI: 10.1002/cncr.24030
27. Vanbrabant T., Fassnacht M., Assie G. et al. Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis. Eur J Endocrinol 2018;179:429–36. DOI: 10.1530/EJE-18-0450
28. Cain D.W., Cidlowski J.A. Immune regulation by glucocorticoids. Nat Rev Immunol 2017;17:233–47. DOI: 10.1038/nri.2017.1
29. Порубаева Э.Э., Пачуашвили Н.В., Урусова Л.С. Мультифакторная оценка прогностических особенностей адренокортикального рака. Архив патологии 2022;84(5):20–7. DOI: 10.17116/patol20228405120 Porubaeva E.E., Pachuashvili N.V., Urusova L.S. Multifactorial assessment of prognostic features of adrenocortical cancer. Arkhiv patologii = Archive of pathology 2022;84(5):20–7. (In Russ.). DOI: 10.17116/patol20228405120
30. Delman A.M., Turner K.M., Griffith A. et al. Minimally invasive surgery for resectable adrenocortical carcinoma: A nationwide analysis. J Surg Res 2022;279:200–7. DOI: 10.1016/j.jss.2022.04.078
31. Basile V., Puglisi S., Calabrese A. et al. Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer. Cancers (Basel) 2020;12(9):2615. DOI: 10.3390/cancers12092615
32. van Koetsveld P.M., Creemers S.G., Dogan F. et al. The efficacy of mitotane in human primary adrenocortical carcinoma cultures. J Clin Endocrinol Metab 2020;105:407–17. DOI: 10.1210/clinem/dgz001
33. Fassnacht M., Assie G., Baudin E. et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1476–90. DOI: 10.1016/j.annonc.2020.08.2099
34. Terzolo M., Zaggia B., Allasino B. et al. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2014;21:159–65. DOI: 10.1097/MED.0000000000000056
35. Puglisi S., Calabrese A., Basile V. et al. Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers (Basel) 2020;12(3):740. DOI: 10.3390/cancers12030740
36. Fassnacht M., Dekkers O., Else T. et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018;179:G1–46. DOI: 10.1530/EJE-18-0608
37. Tang Y., Liu Z., Zou Z. et al. Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: A systematic review and meta-analysis. Biomed Res Int 2018;2018:9362108. DOI: 10.1155/2018/9362108
38. Terzolo M., Fassnacht M., Perotti P. et al. Results of the ADIUVO Study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients. J Endocr Soc 2021;5:A166–7. DOI: 10.1210/jendso/bvab048.336 39. Terzolo M., Fassnacht M. Endocrine tumours: our experience with the management of patients with non-metastatic adrenocortical carcinoma. Eur J Endocrinol 2022;187:R27–40. DOI: 10.1530/EJE-22-0260
40. Fassnacht M., Terzolo M., Allolio B. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366:2189–97. DOI: 10.1056/NEJMoa1200966
41. Thorsson V., Gibbs D.L., Brown S.D. et al. The immune landscape of cancer. Immunity 2018;48:812–30.e14. DOI: 10.1016/j.immuni.2018.03.023
42. G ndisch S., Boeckeler E., Behrends U. et al. Glucocorticoids augment survival and proliferation of tumor cells. Anticancer Res 2012;32:4251–61. PMID: 23060545
43. Landwehr L.-S., Altieri B., Schreiner J. et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer 2020;8(1):e000469. DOI: 10.1136/jitc-2019-000469
44. Huang R., Liu Z., Tian T. et al. The construction and analysis of tumor-infiltrating immune cells and ceRNA networks in metastatic adrenal cortical carcinoma. Biosci Rep 2020;40(3):BSR20200049. DOI: 10.1042/BSR20200049
45. Li X., Gao Y., Xu Z. et al. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods. Cancer Med 2020;9:1161–72. DOI: 10.1002/cam4.2774
46. Tian X., Xu W., Wang Y. Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data. Oncoimmunology 2020;9(1):1784529. DOI: 10.1080/2162402X.2020.1784529
47. Parise I.Z.S., Parise G.A., Noronha L. et al. The prognostic role of CD8+ T lymphocytes in childhood adrenocortical carcinomas compared to Ki-67, PD-1, PD-L1, and the Weiss score. Cancers (Basel) 2019;11(11):1730. DOI: 10.3390/cancers11111730
48. Bondy S., Tajzler C., Hotte S.J. et al. Genomic and clinical correlates of adrenocortical carcinoma in an adult patient with Li–Fraumeni syndrome: a case report. Curr Oncol 2020;28(1):226–32. DOI: 10.3390/curroncol28010025
49. Billon E., Finetti P., Bertucci A. et al. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. Oncoimmunology 2019;8(11):e1655362. DOI: 10.1080/2162402X.2019.1655362
50. Habra M.A., Stephen B., Campbell M. et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 2019;7(1):253. DOI: 10.1186/s40425-019-0722-x
51. Raj N.P., Zheng Y., Kelly V. et al. Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma. J Clin Oncol 2019;37:4112. DOI: 10.1200/JCO.2019.37.15_suppl.4112
52. Carneiro B.A., Konda B., Costa R.B. et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J Clin Endocrinol Metab 2019;104:6193–200. DOI: 10.1210/jc.2019-00600
53. Le Tourneau C., Hoimes C., Zarwan C. et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIn solid tumor trial. J Immunother Cancer 2018;6(1):111. DOI: 10.1186/s40425-018-0424-9
54. Azizi E., Carr A.J., Plitas G. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 2018;174(5):1293–308.e36. DOI: 10.1016/j.cell.2018.05.060
55. Shen C., Wang Y. Ferroptosis Biomarkers for predicting prognosis and immunotherapy efficacy in adrenocortical carcinoma. Arch Med Res 2023;1:45–55. DOI: 10.1016/j.arcmed.2022.12.003
56. Avila Cobos F., Alquicira-Hernandez J., Powell J.E. et al. Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat Commun 2020;11(1):5650. DOI: 10.1038/s41467-020-19015-1
57. Lim B., Lin Y., Navin N. Advancing cancer research and medicine with single-cell genomics. Cancer cell 2020;37(4):456–70. DOI: 10.1016/j.ccell.2020.03.008
58. Xu F., Guan Y., Ma Y. et al. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma. Aging (Albany NY) 2021;13(8):11919–41. DOI: 10.18632/aging.202896
59. Giesen C., Wang H.A., Schapiro D. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods 2014;11(4):417–22. DOI: 10.1038/nmeth.2869
60. Huang J., Qin F., Lai X. et al. Exploring heterogeneity of tumor immune cells and adrenal cells in aldosterone-producing adenomas using single-cell RNA-seq and investigating differences by sex. Heliyon 2023;9(3):e14357. DOI: 10.1016/j.heliyon.2023.e14357
Авторы заявляют об отсутствии конфликта интересов.
Работа выполнена без спонсорской поддержки.
Пачуашвили Н. В., Тертычный А. С., Демура Т. А. и др. Иммунный ландшафт адренокортикального рака: новые перспективы прогноза и терапии. Онкопатология 2024;7(1):19–30. DOI: https://doi.org/10.17650/2618‑7019‑2024‑7‑1-19‑30
![]() |
2024 №3 (Том 7) Скачать>> |